



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigios Tower, Netaji Subhash Place, Delhi-110034, India

Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

24/07/2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI Listing Regulations”).

Pursuant to the Regulation 30 of the SEBI Listing Regulations, read with the SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and in accordance with the Company's Policy on Determination of Materiality for Disclosure of Events or Information, the Company has identified material litigation requiring disclosure under sub-paragraph 8 of paragraph B of Schedule III to the Listing Regulations, as per the revised materiality criteria prescribed in the SEBI Amendments. The details of the material litigation is enclosed as **Annexure-A**.

We request you to take the above on record and treat the same as compliance under the applicable provisions of the SEBI Listing Regulations.

Thanking You,
For M/s. Titan Biotech Limited

Charanjit Singh
(Company Secretary and Compliance Officer)
M. No.: A12726

R.O. & Works: Unit I: A-902A, RIICO Industrial Aea, Phase III, Bhiwadi-301019, Rajasthan

Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: hrd@titanbiotechltd.com,accounts@titanbiotechltd.com,,purchase@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.tmmedia.in



ANNEXURE-A

Disclosure as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, and SEBI Circular SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023:

At the time of becoming the party:		
(a)	Brief details of litigation viz. name(s) of the opposing party, court / tribunal / agency where litigation is filed, brief details of dispute / litigation.	NGenious Solutions Private Limited has sent a notice invoking arbitration proceedings against Titan Biotech Limited, all directors and KMP's for the recovery of disputed outstanding dues.
(b)	Expected financial implications, if any, due to compensation, penalty etc.	NGenious Solutions Private Limited's claim is to remit a sum of Rs. 10,62,410/- plus GST being the total outstanding dues comprising of Balance Outstanding of Rs. 9,13,920/- (excl. GST) plus compounded interest calculated till 15/07/2025 of Rs. 98,490/- (excl. GST) plus compensation of Rs. 50,000/- (excl. GST).
(c)	quantum of claims, if any.	As explained under item (b) above
Regularly till the litigation is concluded or dispute is resolved:		
(a)	The details of any change in the status and / or any development in relation to such proceedings.	will be informed in due course
(b)	In the case of litigation against key management personnel or its promoter or ultimate person in control, regularly provide details of any change in the status and / or any development in relation to such proceedings.	will be informed in due course
(c)	In the event of settlement of the proceedings, details of such settlement including terms of the settlement, compensation/penalty paid (if any) and impact of such settlement on the financial position of the listed entity.	will be informed in due course